Crizotinib Ups PFS in ALK-Positive NSCLC

The ALK-inhibitor crizotinib leads to longer progression-free survival than chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC), according to results of a phase III clinical trial.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news